Too often we define the Medtech sector by the number of dollars raised, IPOs helped or companies sold. But the focus neglects the very foundation of the sector - the People. Join the Medtech Talk Podcast each week to hear from entrepreneurs, investors and executives who spend their days developing the tools that make sick people well and health care more efficient.
Host Geoff Pardo talks with Adam Berman, CEO of Alleviant Medical, about the groundbreaking device treating heart failure without hardware or permanent implants. The Alleviant device mitigates shortness of breath in patients with diastolic heart failure by leaving behind a shunt cut from interatrial septum tissue. The shunt moves blood from the left atrium to the right, diminishing pressure on the lungs. Berman speaks about his start in biomedical engineering, gaining invaluable experience in the operating room, developing sales tactics and industry knowledge as a medical device field representative, and switching gears to create novel devices for cardiac care.
Adam L. Berman is CEO of Alleviant Medical, a medical system designing a minimally invasive medical device to treat heart failure. Adam has 20 years of experience in R&D, Sales and Operational leadership roles for start-up medical device companies creating minimally invasive technology. He has been responsible for developing and commercializing cardiovascular laser ablation systems, anastomotic devices, and robotic surgical systems. His past companies include TVA Medical, Coalescent Surgical, Inc. (now Medtronic), MedicalCV, and Computer Motion, Inc. (now Intuitive Surgical). Adam received his BSE Magna Cum Laude in Biomedical Engineering from Rensselaer Polytechnic Institute and his MSE in Bioengineering from the University of Washington.